Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.200
+0.020 (1.69%)
Aug 13, 2025, 4:00 PM - Market closed
Rein Therapeutics Employees
Rein Therapeutics had 11 employees as of December 31, 2024. The number of employees decreased by 4 or -26.67% compared to the previous year.
Employees
11
Change (1Y)
-4
Growth (1Y)
-26.67%
Revenue / Employee
n/a
Profits / Employee
-$5,570,091
Market Cap
27.66M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RNTX News
- 7 weeks ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 2 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
- 2 months ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 3 months ago - Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference - PRNewsWire
- 3 months ago - Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 3 months ago - Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 3 months ago - Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 3 months ago - Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - PRNewsWire